Tender detail
Non-exclusive discount agreement for medicines containing dihydrocodeine
Summary
DAK-Gesundheit intends to conclude non-exclusive discount agreements with interested pharmaceutical companies for medicines containing dihydrocodeine (ATC R05DA14). The agreements will run from 1 December 2026 to 30 November 2028, with an option for one 12-month extension. They will also end earlier if an exclusive agreement for the active ingredient takes effect.
More tender information after sign-in
The public view shows key tender details. Sign in to open official links, documents and AI tender support.